SFERA Archivio dei prodotti della Ricerca dell'Università di Ferrara

CIANCETTA, Antonella
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 1.173
EU - Europa 262
AS - Asia 129
Continente sconosciuto - Info sul continente non disponibili 1
OC - Oceania 1
SA - Sud America 1
Totale 1.567
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.171
IT - Italia 85
CN - Cina 70
TR - Turchia 52
PL - Polonia 38
UA - Ucraina 38
GB - Regno Unito 36
DE - Germania 27
SE - Svezia 21
FI - Finlandia 10
BE - Belgio 5
HK - Hong Kong 4
CA - Canada 2
RU - Federazione Russa 2
CL - Cile 1
EU - Europa 1
IR - Iran 1
NZ - Nuova Zelanda 1
TW - Taiwan 1
VN - Vietnam 1
Totale 1.567
Salva come PNG Salva come JPEG
Città #
Chandler 138
Fairfield 138
Ashburn 117
Ann Arbor 93
Houston 91
Woodbridge 85
Jacksonville 54
Ferrara 51
Wilmington 50
Seattle 49
Princeton 46
Cambridge 44
Warsaw 38
Izmir 25
Shanghai 19
San Diego 18
Beijing 12
Washington 12
London 11
Nanjing 11
Falls Church 9
Boardman 7
Brussels 5
Changsha 5
Chicago 5
Milan 5
Redmond 5
Ferrara di Monte Baldo 4
Hong Kong 4
New York 4
Norwalk 4
Addison 3
Chiswick 3
Jiaxing 3
Jinan 3
Zhengzhou 3
Bremen 2
Hebei 2
Kilburn 2
Kunming 2
Nanchang 2
Novara 2
Tianjin 2
Bologna 1
Brentford 1
Camerino 1
Changchun 1
Dearborn 1
Dong Ket 1
Dunedin 1
Guangzhou 1
Hangzhou 1
Helsinki 1
Hounslow 1
Indiana 1
Islington 1
Kashan 1
Lanzhou 1
Mestre 1
Mountain View 1
Novokuznetsk 1
Padova 1
Palo del Colle 1
San Lazzaro di Savena 1
Saskatoon 1
Shenyang 1
Southfield 1
Southwark 1
Taipei 1
Tappahannock 1
Toronto 1
Venice 1
Wandsworth 1
Totale 1.218
Salva come PNG Salva come JPEG
Nome #
5,7-Disubstituted-[1,2,4]triazolo[1,5-a][1,3,5]triazines as pharmacological tools to explore the antagonist selectivity profiles toward adenosine receptors 147
A3 Adenosine Receptors as Modulators of Inflammation: From Medicinal Chemistry to Therapy 143
Pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidines and Structurally Simplified Analogs. Chemistry and SAR Profile as Adenosine Receptor Antagonists 120
null 118
2-Arylpyrazolo[4,3-d]pyrimidin-7-amino derivatives as new potent and selective human A3 adenosine receptor antagonists. Molecular modeling studies and pharmacological evaluation 117
The influence of the 1-(3-Trifluoromethyl-Benzyl)-1H-Pyrazole-4-yl moiety on the adenosine receptors affinity profile of pyrazolo[4,3-e][1,2,4]Triazolo[1,5-c] pyrimidine derivatives 116
null 90
Structural refinement of pyrazolo[4,3-d]pyrimidine derivatives to obtain highly potent and selective antagonists for the human A3 adenosine receptor 79
7-Amino-2-phenylpyrazolo[4,3-d]pyrimidine derivatives: Structural investigations at the 5-position to target human A(1) and A(2A) adenosine receptors. Molecular modeling and pharmacological studies 69
Revisiting a receptor-based pharmacophore hypothesis for human A(2A) adenosine receptor antagonists 51
A 2a adenosine receptor: Structures, modeling, and medicinal chemistry 44
Bridging molecular docking to membrane molecular dynamics to investigate GPCR-ligand recognition: The human A2A adenosine receptor as a key study 29
Enhancing Ligand and Protein Sampling Using Sequential Monte Carlo 29
A3 adenosine receptor activation mechanisms: molecular dynamics analysis of inactive, active, and fully active states 25
DockBench: An Integrated Informatic Platform Bridging the Gap between the Robust Validation of Docking Protocols and Virtual Screening Simulations 25
Demystifying P2Y1 Receptor Ligand Recognition through Docking and Molecular Dynamics Analyses 24
Deciphering the Complexity of Ligand-Protein Recognition Pathways Using Supervised Molecular Dynamics (SuMD) Simulations 23
Advances in Computational Techniques to Study GPCR-Ligand Recognition 21
Conjugates between minor groove binders and Zn(II)-tach complexes: Synthesis, characterization, and interaction with plasmid DNA 21
Aquaporin inhibition by gold(III) compounds: New insights 20
A QM/MM study of the binding of RAPTA ligands to cathepsin B 20
Probe Confined Dynamic Mapping for G Protein-Coupled Receptor Allosteric Site Prediction 20
Design and in Vivo Characterization of A 1 Adenosine Receptor Agonists in the Native Ribose and Conformationally Constrained (N)-Methanocarba Series 20
Activation of carboplatin by chloride ions: a theoretical investigation 19
Novel Aryl Sulfonamide Derivatives as NLRP3 Inflammasome Inhibitors for the Potential Treatment of Cancer 18
Activation of Carboplatin by Carbonate 18
New Trends in Inspecting GPCR-ligand Recognition Process: the Contribution of the Molecular Modeling Section (MMS) at the University of Padova 16
Sensitivity of Binding Free Energy Calculations to Initial Protein Crystal Structure 15
Rationalization of the inhibition activity of structurally related organometallic compounds against the drug target cathepsin B by DFT 15
“Exploring the Recognition Pathway at the Human A2A Adenosine Receptor of the Endogenous Agonist Adenosine using Supervised Molecular Dynamics Simulations” 15
Alternative quality assessment strategy to compare performances of GPCR-ligand docking protocols: the human adenosine A(2A) receptor as a case study 15
“Bitopic Fluorescent Antagonists of the A2A Adenosine Receptor Based on Pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidin-5-amine Functionalized Congeners” 14
Understanding allosteric interactions in G protein-coupled receptors using Supervised Molecular Dynamics: A prototype study analysing the human A3 adenosine receptor positive allosteric modulator LUF6000 14
Pyrimidine nucleotides containing a (S)-methanocarba ring as P2Y6 receptor agonists 12
Structure activity relationship of 2-arylalkynyl-adenine derivatives as human A3 adenosine receptor antagonists 12
Structure-Based Scaffold Repurposing for G Protein-Coupled Receptors: Transformation of Adenosine Derivatives into 5HT2B/5HT2C Serotonin Receptor Antagonists 11
Structure-Based Design of 3-(4-Aryl-1H-1,2,3-Triazol-1-yl)-Biphenyl Derivatives as P2Y14 Receptor Antagonists 11
Repurposing of a nucleoside scaffold from adenosine receptor agonists to opioid receptor antagonists 11
Structure-Guided Modification of Heterocyclic Antagonists of the P2Y 14 Receptor 10
HETEROCYCLIC P2Y14 RECEPTOR ANTAGONISTS 10
Structural probing and molecular modeling of the A3 adenosine receptor: A focus on agonist binding 8
South (S)- and north (N)-methanocarba-7-deazaadenosine analogues as inhibitors of human adenosine kinase 8
Synthesis and Spectroscopic Characterisation of a Heterodinuclear Iron(III)-Copper(II) Complex Based on an Asymmetric Dinucleating Ligand System 8
Perturbation of fluid dynamics properties of water molecules during G protein-coupled receptor-ligand recognition: the human A2A adenosine receptor as a key study 7
Influence of key amino acid mutation on the active site structure and on folding in acetyl-CoA synthase: A theoretical perspective 7
Targeting Aquaporin Function: Potent Inhibition of Aquaglyceroporin-3 by a Gold-Based Compound 7
Polypharmacology of conformationally locked methanocarba nucleosides 7
Purine (N)-Methanocarba Nucleoside Derivatives Lacking an Exocyclic Amine as Selective A3 Adenosine Receptor Agonists 6
Implementing the “Best Template Searching” tool into Adenosiland platform 4
In silico 3D modeling of binding activities 4
Advances in GPCR modeling evaluated by the GPCR Dock 2013 assessment: Meeting new challenges 2
Breakthrough in GPCR Crystallography and Its Impact on Computer-Aided Drug Design 2
“Protein-ligand docking: virtual screening and applications to drug discovery” 2
Enhancing torsional sampling using fully adaptive simulated tempering 1
Totale 1.680
Salva come PNG Salva come JPEG
Categoria #
all - tutte 13.513
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 405
Totale 13.918
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/2019128 0 0 0 0 0 0 0 0 0 26 33 69
2019/2020216 31 8 7 36 14 27 20 19 19 17 9 9
2020/2021221 13 7 15 20 7 24 7 25 16 45 32 10
2021/2022366 2 16 6 100 16 5 18 61 20 7 13 102
2022/2023313 51 22 24 21 40 26 8 44 47 9 13 8
2023/2024204 16 25 27 12 28 48 14 24 7 3 0 0
Totale 1.680